Abstract
The occurrence of macular edema as an adverse effect of fingolimod is well documented. Treatment modalities used to manage fingolimod-associated macular edema (FAME) have included nonsteroidal anti-inflammatory agents and sub-tenon injection. We describe two cases where intravitreal injection is used to successfully treat FAME in patients who were previously unsuccessfully treated with topical nonsteroidal anti-inflammatories.
Original language | English |
---|---|
Pages (from-to) | 249-251 |
Number of pages | 3 |
Journal | Multiple Sclerosis |
Volume | 21 |
Issue number | 2 |
DOIs | |
Publication status | Published - 17 Feb 2015 |
Keywords
- Edema
- Fingolimod
- Multiple sclerosis
- Steroid